Search Results - "Redman, M W"

Innovative Clinical Trials: The LUNG-MAP Study by Steuer, CE, Papadimitrakopoulou, V, Herbst, RS, Redman, MW, Hirsch, FR, Mack, PC, Ramalingam, SS, Gandara, DR

“…Although the proportion of patients with squamous cell carcinoma of the lung has declined over the last two decades, the disease is still fatal for tens of…”
Get full text

The effect of the UGT1A128 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis by Dias, M M, Pignon, J-P, Karapetis, C S, Boige, V, Glimelius, B, Kweekel, D M, Lara, P N, Laurent-Puig, P, Martinez-Balibrea, E, Páez, D, Punt, C J A, Redman, M W, Toffoli, G, Wadelius, M, McKinnon, R A, Sorich, M J

“…To date, studies of irinotecan pharmacogenetics have mostly focused on the effect of the UGT1A1*28 allele on irinotecan-related toxicity. However, the clinical…”
Get full text

The hazards of randomized phase II trials by Lara, P.N., Redman, M.W.

Get full text

EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC by Hirsch, Fred R., Redman, Mary W., Moon, James, Agustoni, Francesco, Herbst, Roy S., Semrad, Thomas J., Varella-Garcia, Marileila, Rivard, Chris J., Kelly, Karen, Gandara, David R., Mack, Philip C.

“…The phase III S0819 trial investigated addition of cetuximab to first-line chemotherapy (CT) in NSCLC. Subgroup analyses suggested an OS benefit among patients…”
Get full text

Acquired Resistance to Targeted Therapies Against Oncogene-Driven Non–Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications by Gandara, David R, Li, Tianhong, Lara, Primo N, Kelly, Karen, Riess, Jonathan W, Redman, Mary W, Mack, Philip C

“…Abstract In the emerging era of targeted therapy for advanced-stage non–small-cell lung cancer, it is becoming increasingly important to anticipate underlying…”
Get full text

Systematic evaluation of the impact of disease progression (DP) date determination on progression-free survival (PFS) in advanced lung cancer: A joint North Central Cancer Treatment Group (NCCTG) and Southwest Oncology Group (SWOG) investigation by Mandrekar, S. J., Qi, Y., Allen-Ziegler, K., Hillman, S. L., Redman, M. W., Schild, S. E., Gandara, D. R., Adjei, A. A.

“…Abstract only…”
Get full text

The hazards of randomized phase II trials by Lara, P N, Redman, M W

Get full text

KRAS and EGFR mutations in the molecular epidemiology of NSCLC: Interim analysis of S0424 by Mack, P. C., Redman, M. W., Chansky, K., Matsumoto, S., Holland, W. S., Lara, P., Ambrosone, C. B., Gandara, D. R.

“…Abstract only…”
Get full text

SWOG S0342 and S0536: Expression of EGFR protein and markers of epithelial-mesenchymal transformation (EMT) in cetuximab/chemotherapy-treated non-small cell lung cancer (NSCLC) by Franklin, W. A., Gandara, D. R., Kim, E. S., Herbst, R. S., Moon, J., Redman, M. W., Olsen, C., Hirsch, F. R., Mack, P., Kelly, K.

“…Abstract only 11076 Background: High EGFR gene copy number is associated with efficacy in NSCLC patients (pts) receiving combined chemotherapy and cetuximab…”
Get full text

S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study by Gandara, D., Kim, E. S., Herbst, R. S., Moon, J., Redman, M. W., Dakhil, S. R., Hirsch, F., Mack, P. C., Franklin, W., Kelly, K.

“…Abstract only 8015 Background: Cetuximab (CX) plus platinum-based chemotherapy improves overall survival (OS) in advanced NSCLC (FLEX). SWOG previously showed…”
Get full text

Infectious ribonucleic acid derived from enteroviruses by SPRUNT, K, REDMAN, W M, ALEXANDER, H E

Get more information

Factors influencing degree of infectivity of enterovirus ribonucleic acid by SPRUNT, K, REDMAN, W M, KOENIG, S, ALEXANDER, H E

Get more information

Combination of Antigenic Traits of Type 1 and Type 2 Poliovirus by Sprunt, Katherine, Redman, Winifred M, Alexander, Hattie E

“…Summary Growth of types 1 and 2 polioviruses in a 1:1 ratio in the same monkey kidney cell culture resulted in a virus population which apparently combined…”
Get full text

Alternative measures predicting clinical benefit in advanced non-small cell lung cancer (NSCLC) from Southwest Oncology Group (SWOG) randomized trials: Implications for clinical trial design by Lara, P. N., Redman, M. W., Kelly, K., Edelman, M. J., Williamson, S. K., Crowley, J. J., Gandara, D. R.

“…Abstract only 7006 Background: Although objective response (CR/PR) & overall survival (OS) are typical efficacy measures for new treatments in advanced stage…”
Get full text

Abstract P4-22-11: Combined targeted therapies for advanced triple negative breast cancer: A phase II trial of nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib by Specht, JM, Gadi, VK, Gralow, JR, Korde, LA, Linden, HM, Salazar, LG, Rodler, ET, Cundy, A, Buening, BJ, Baker, KK, Redman, MW, Kurland, BF, Garrison, MA, Smith, JC, vanHaelst, C, Anderson, JE

“…Abstract Background: Chemotherapy remains the mainstay of therapy for patients with metastatic triple negative breast cancer (TNBC). We hypothesized that the…”
Get full text

Do General Dimensions of Quality of Life Add Clinical Value to Symptom Data? by Moinpour, Carol M., Donaldson, Gary W., Redman, Mary W.

“…Since global health-related quality of life (GHRQL) reflects broad impacts of treatment, its assessment in an advanced-stage disease trial should add valuable…”
Get full text

Elevated osteopontin (OPN) plasma levels are highly prognostic in advanced non-small cell lung cancer (NSCLC): Analysis of SWOG S0003 by Mack, P. C., Redman, M. W., Chansky, K., Williamson, S. K., Farneth, N., Lara, P. N., Le, Q., Gumerlock, P. H., Crowley, J. J., Gandara, D. R.

“…Abstract only 7198 Background: OPN is a secreted glycoprotein with a diverse array of functions, including induction of uPA & increased cell migration. OPN has…”
Get full text

Lung-MAP--framework, overview, and design principles by Ferrarotto, Renata, Redman, Mary W, Gandara, David R, Herbst, Roy S, Papadimitrakopoulou, Vassiliki A

“…Metastatic lung squamous cell carcinoma (SCC) is a common disease with limited therapeutic options and poor patient outcomes. Standard "all comers" clinical…”
Get more information

Preeclampsia: simplified or still miles to go.... response to Jadli and co-authors by Redman, Christopher W., MD, Staff, Anne Cathrine, MD, PhD

Get full text

The long-term outcome in surviving infants with Apgar zero at 10 minutes: a systematic review of the literature and hospital-based cohort by Harrington, Deborah J., MD, Redman, Christopher W., MD, Moulden, Mary, Greenwood, Catherine E., MD

“…Objective The purpose of this study was to investigate the outcomes of infants who had Apgar scores of zero at 10 minutes and were resuscitated successfully…”
Get full text